AstraZeneca signs $1.5 billion AI drug discovery collaboration with insitro for cardiometabolic diseases
AstraZeneca and insitro have entered a $1.5 billion AI-enabled drug discovery collaboration targeting difficult-to-treat cardiometabolic diseases.
The agreement will use insitro's Virtual Human AI platform to identify therapeutic targets and develop candidates for metabolic dysfunction-associated steatohepatitis and cardiomyopathies, with AstraZeneca securing exclusive worldwide rights to selected programmes.
insitro will receive $40 million upfront and may earn approximately $1.46 billion in development and commercial milestones plus potential single-digit royalties, with most of the headline deal value contingent on future progress.
Field | Content |
Article Type | Deals |
Companies | AstraZeneca; insitro |
Deal Type | Strategic research collaboration and licensing agreement |
Potential Deal Value | Approximately $1.5 billion excluding royalties |
Upfront Payment | $40 million |
Potential Milestone Payments | Approximately $1.46 billion in development and commercial milestones |
Royalties | Potential single-digit royalties |
Technology | insitro Virtual Human AI platform |
Therapeutic Areas | Cardiometabolic diseases; metabolic dysfunction-associated steatohepatitis; cardiomyopathies |
Research Focus | AI-enabled therapeutic target identification and drug candidate development |
Licensing Rights | Exclusive worldwide rights to selected programmes for AstraZeneca |
Development Stage | Research and discovery |
Geography | Worldwide |
What Happened | AstraZeneca entered a strategic collaboration and licensing agreement with insitro to discover and develop treatments for difficult-to-treat cardiometabolic diseases. |
Why It Matters | The partnership combines AI-driven human disease modelling with pharmaceutical development capabilities to investigate therapeutic targets in areas of substantial unmet medical need. |
Strategic Rationale | AstraZeneca gains access to insitro's AI platform and selected programmes while insitro receives upfront funding and contingent development and commercial opportunities. |
Key Takeaway | The agreement offers approximately $1.5 billion in potential consideration but only $40 million is identified as an upfront payment. |
What to Watch | Target identification, programme selection, preclinical candidate development, milestone achievements and clinical development plans. |
Primary Source | AstraZeneca |
Relevant Date | 15 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comments